Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>Zacks Small-Cap Research Note for PolyPid Ltd. (PYPD)</li></ul>

Zacks Small-Cap Research Note for PolyPid Ltd. (PYPD)

PYPD: Positive Topline Data From D-PLEX100 Trial Contributes to Multiple Subsequent Benefits

Assessing & Advancing Lead Candidate D-PLEX100 Through Clinical Trials to Improve Surgical Outcomes

PolyPid Ltd - Assessing & Advancing Lead Candidate

Israel

PolyPid Ltd. operates as a pharmaceutical company. The Company discovers, develops, and commercializes antibiotic drugs for the prevention of surgical infections. PolyPid serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00